Ockenga J, Tietge U J F, Böker K H W, Manns M P, Brabant G, Bahr M J
Department of Gastroenterology, Hepatology and Endocrinology, Medizinische Hochschule Hannover, Hannover, Germany.
Aliment Pharmacol Ther. 2007 Jun 1;25(11):1301-9. doi: 10.1111/j.1365-2036.2007.03327.x.
Alteration of the leptin system appears to play a role in the inflammatory-metabolic response in catabolic diseases such as chronic liver diseases.
To investigate the association between leptin components, inflammatory markers and hepatic energy and substrate metabolism.
We investigated in vivo hepatic substrate and leptin metabolism in 40 patients employing a combination of arterial and hepatic vein catheterization techniques and hepatic blood flow measurements. In addition to metabolic, inflammatory and neuroendocrine parameters, circulating levels of free leptin, bound leptin and soluble leptin receptor were determined.
Compared with controls, bound leptin and soluble leptin receptor levels were significantly elevated in cirrhosis, while free leptin did not increase. In cirrhosis bound leptin was correlated with soluble leptin receptor (r = 0.70, P < 0.001). Free leptin was positively correlated with metabolic parameters such as energy storage (body fat mass; r = 0.36, P < 0.05), insulin and insulin resistance (r = 0.48; r = 0.46, P < 0.01) as well as with hepatic glucose and energy release (r = 0.35 and r = 0.40, P < 0.05). In contrast, bound leptin and soluble leptin receptor were linked to proinflammatory cytokines and sympathetic activity (r = 0.61 and r = 0.56, P < 0.01).
The components of the leptin system (free leptin, bound leptin and soluble leptin receptor) have distinct roles in metabolic and inflammatory processes in patients with liver cirrhosis. The better understanding of this metabolic and inflammatory tissue-repair response may lead to innovative new therapeutic strategies in liver disease as well as in various other catabolic diseases.
瘦素系统的改变似乎在诸如慢性肝病等分解代谢性疾病的炎症-代谢反应中起作用。
研究瘦素各组分、炎症标志物与肝脏能量及底物代谢之间的关联。
我们采用动脉和肝静脉插管技术及肝血流测量相结合的方法,对40例患者的肝脏底物和瘦素代谢进行了体内研究。除代谢、炎症和神经内分泌参数外,还测定了游离瘦素、结合瘦素和可溶性瘦素受体的循环水平。
与对照组相比,肝硬化患者结合瘦素和可溶性瘦素受体水平显著升高,而游离瘦素未增加。在肝硬化患者中,结合瘦素与可溶性瘦素受体相关(r = 0.70,P < 0.001)。游离瘦素与能量储存(体脂量;r = 0.36,P < 0.05)、胰岛素及胰岛素抵抗(r = 0.48;r = 0.46,P < 0.01)等代谢参数以及肝脏葡萄糖和能量释放(r = 0.35和r = 0.40,P < 0.05)呈正相关。相反,结合瘦素和可溶性瘦素受体与促炎细胞因子和交感神经活性相关(r = 0.61和r = 0.56,P < 0.01)。
瘦素系统的各组分(游离瘦素、结合瘦素和可溶性瘦素受体)在肝硬化患者的代谢和炎症过程中具有不同作用。更好地理解这种代谢和炎症组织修复反应可能会为肝病以及其他各种分解代谢性疾病带来创新的新治疗策略。